Symrise AG

  • WKN: SYM999
  • ISIN: DE000SYM9999
  • Land: Deutschland

Nachricht vom 07.08.2019 | 16:02

Dr. Winfried Steeger has been elected as new Chairman of the Symrise Supervisory Board

DGAP-News: Symrise AG / Key word(s): Personnel

07.08.2019 / 16:02
The issuer is solely responsible for the content of this announcement.

  • Dr. Winfried Steeger succeeds Dr. Thomas Rabe, who is resigning as Chairman of the Supervisory Board at his own request effective 7 August 2019
  • Dr. Steeger is a member of the Supervisory Board of Symrise AG since 2012 and has many years of leadership experience and recognized expertise

The Supervisory Board of Symrise AG has elected Dr. Winfried Steeger (69) as Chairman of the Supervisory Board at its ordinary meeting today. Dr. Steeger succeeds Dr. Thomas Rabe (54), who will resign as Chairman at his own request but will continue to serve the Company in his function as a member of the Supervisory Board. Dr. Steeger is a lawyer and Managing Director of the Jahr Group. He has been a member of the Supervisory Board of Symrise AG since 2012. His election as Chairman ensures continuity for the successful further development of Symrise.

"I have been with Symrise for a long time and look forward to advising the Company now as Chairman of the Supervisory Board. On behalf of the Supervisory Board, I would like to thank Dr. Rabe for his excellent work. We are pleased that he will stay with us as a valuable member of the Supervisory Board. We will continue our future tasks constructively together with the Executive Board of Symrise AG," said Dr. Winfried Steeger.

"We very much welcome that Dr. Steeger has assumed the position of Chairman of the Supervisory Board of Symrise AG. Dr. Steeger is a proven expert with many years of leadership experience. He brings the best qualifications to provide the Executive Board with comprehensive advice," said Dr. Heinz-Jürgen Bertram, CEO of Symrise AG.

Dr. Steeger began his professional career in 1979 as a legal counsel and later as a partner at Freshfields Bruckhaus Deringer L.L.P. Since 2011 he has been Managing Director of the Jahr Group in Hamburg. On 15 May 2012, he was elected to the Supervisory Board by the Annual General Meeting of Symrise AG.

Dr. Rabe announced his resignation as Chairman of the Supervisory Board already in April 2019. It is related to his election to the Supervisory Board of Adidas.


About Symrise:

Symrise is a global supplier of fragrances, flavorings, cosmetic active ingredients and raw materials, as well as functional ingredients. Its clients include manufacturers of perfumes, cosmetics, food and beverages, the pharmaceutical industry and producers of nutritional supplements and pet food.

Its sales of approximately EUR 3.2 billion in the 2018 fiscal year make Symrise a leading global provider. Headquartered in Holzminden, Germany, the Group is represented with over 100 sites in Europe, Africa, the Middle East, Asia, the United States and Latin America.

Symrise works with its clients to develop new ideas and market-ready concepts for products that form an indispensable part of everyday life. Economic success and corporate responsibility are inextricably linked as part of this process. Symrise - always inspiring more.


Media contact: Investor contact:
Bernhard Kott Tobias Erfurth
Phone: +49 (0)5531 90-1721 Phone: +49 (0)5531 90-1879
Email: Email:
Social media:

07.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Anleihe im Fokus

„Semper idem Underberg AG: Emission neuer Unternehmensanleihe 2019/2025“

- Emissionsvolumen: bis zu 60 Mio. Euro
- Anleihenumtausch: 23.010. bis 06.11.2019
- Neuzeichnung: 07.11. bis 12.11.2019
- Stückelung / Mindestanlage: 1.000 Euro
- Zinssatz (Kupon):
Liegt in einer Spanne von 4,00 % bis 4,25 % p.a.
- Laufzeit: 6 Jahre
- Zinszahlung: jährlich, jeweils am 18. November (nachträglich), erstmals am 18. November 2020
- Rückzahlungskurs: 100%
- Fälligkeit: 18. November 2025
- Listing: Listing im Freiverkehr (Open Market) der Frankfurter Wertpapierbörse vorgesehen


Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Continental AG: Continental AG berücksichtigt im dritten Quartal 2019 nicht zahlungswirksame Wertminderungen und Restrukturierungsrückstellungen

22. Oktober 2019, 13:34

Aktuelle Research-Studie


Original-Research: CO.DON AG (von Sphene Capital GmbH): Buy

21. Oktober 2019